Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.84 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.62 |
| ▸ | F10 | P00742 | 5/20 | 0.58 |
| ▸ | PLAT | P00750 | 4/20 | 0.58 |
| ▸ | KLK1 | P06870 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 4/20 | 0.54 |
| ▸ | PROC | P04070 | 2/20 | 0.54 |
| ▸ | F9 | P00740 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783917 | 1.00 | F11 (0.84) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1920703 | 0.91 | F11 (1.00) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1196980 | 0.91 | F11 (0.89) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1921166 | 0.86 | F11 (0.85) | F11KLKB1F10PLATPLG | |
| SCHEMBL27745598 | 0.86 | F11 (0.85) | F11KLKB1F10PLATPLG | |
| SCHEMBL13547495 | 0.86 | F11 (0.74) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1196595 | 0.85 | F11 (0.89) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1197358 | 0.85 | F11 (0.88) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL13034548 | 0.85 | F11 (0.85) | F11KLKB1F10PLATKLK1 | |
| SCHEMBL1196729 | 0.85 | F11 (0.73) | F11KLKB1F10PLATKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | F11 1/4885KLKB1 752/4885F10 3/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | F11 1/4885KLKB1 859/4885F10 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.